Abstract
This study investigates the effects of mefepronic acid (MA), a PPAR-α agonist, on hepatic metabolic functions and reproduction of postpartum dairy cows. Sixty Friesian cows were divided into Group A (administered 5g of MA IM, within 24 hrs after calving, on the 3rd and 5th day postpartum) and Group B (control). All the cows were blood sampled within 24 hrs of calving (Day 0), on Day 3, 5, 10, 15, 30, and 40 postpartum. On plasma, metabolic and biochemical parameters were determined. Liver biopsies were performed on Day 0, 15 and 30 for the evaluation of hepatic lipid and glycogen content. Reproductive parameters were also evaluated.
In Group A, blood HDL, glucose and cholesterol increased till the end of the study, in accordance with the histological results. PPAR-α immunopositive cells increased in liver slices of Group A, too. Reproductive parameters improved in Group A. This study highlights the beneficial effects of mefepronic acid on the hepatic metabolism and reproductive parameters of post-partum dairy cows.
Keywords: Dairy cow, fatty acids, lipid, liver metabolism, mefepronic acid, reproduction.
Endocrine, Metabolic & Immune Disorders - Drug Targets
Title:Effects of Mefepronic Acid (2-Phenoxy-2-Methyl Propionic Acid) on Hepatic Metabolism and Reproductive Parameters in Postpartum Dairy Cows
Volume: 14 Issue: 2
Author(s): Annalisa Rizzo, Carlo Gazza, Maddalena Mutinati, Salvatore Desantis, Sara Zizza, Giovanni D'Onghia, Gianfranco D'Onghia, Marianna Pantaleo and Raffaele L. Sciorsci
Affiliation:
Keywords: Dairy cow, fatty acids, lipid, liver metabolism, mefepronic acid, reproduction.
Abstract: This study investigates the effects of mefepronic acid (MA), a PPAR-α agonist, on hepatic metabolic functions and reproduction of postpartum dairy cows. Sixty Friesian cows were divided into Group A (administered 5g of MA IM, within 24 hrs after calving, on the 3rd and 5th day postpartum) and Group B (control). All the cows were blood sampled within 24 hrs of calving (Day 0), on Day 3, 5, 10, 15, 30, and 40 postpartum. On plasma, metabolic and biochemical parameters were determined. Liver biopsies were performed on Day 0, 15 and 30 for the evaluation of hepatic lipid and glycogen content. Reproductive parameters were also evaluated.
In Group A, blood HDL, glucose and cholesterol increased till the end of the study, in accordance with the histological results. PPAR-α immunopositive cells increased in liver slices of Group A, too. Reproductive parameters improved in Group A. This study highlights the beneficial effects of mefepronic acid on the hepatic metabolism and reproductive parameters of post-partum dairy cows.
Export Options
About this article
Cite this article as:
Rizzo Annalisa, Gazza Carlo, Mutinati Maddalena, Desantis Salvatore, Zizza Sara, D'Onghia Giovanni, D'Onghia Gianfranco, Pantaleo Marianna and Sciorsci L. Raffaele, Effects of Mefepronic Acid (2-Phenoxy-2-Methyl Propionic Acid) on Hepatic Metabolism and Reproductive Parameters in Postpartum Dairy Cows, Endocrine, Metabolic & Immune Disorders - Drug Targets 2014; 14 (2) . https://dx.doi.org/10.2174/1871530314666140223184913
DOI https://dx.doi.org/10.2174/1871530314666140223184913 |
Print ISSN 1871-5303 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3873 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
New Insights into the Modulation of Immune Response by Fasciola hepatica Excretory-Secretory Products
Current Immunology Reviews (Discontinued) Microglial Activation and its Implications in the Brain Diseases
Current Medicinal Chemistry The Secretin/Pituitary Adenylate Cyclase-Activating Polypeptide/ Vasoactive Intestinal Polypeptide Superfamily in the Central Nervous System
Central Nervous System Agents in Medicinal Chemistry Therapeutical Potential of CB<sub>2</sub> Receptors in Immune-Related Diseases
Current Molecular Pharmacology JAK3 Inhibitors in Organ Transplantation and Autoimmune Disease
Recent Patents on Inflammation & Allergy Drug Discovery Cross-Talk Between NO Synthase Isoforms in Neuro-Inflammation: Possible Implications in HIV-Associated Neurocognitive Disorders
Current Medicinal Chemistry The Study of HLA Class II and Autoimmune Diabetes
Current Molecular Medicine Statins And Stroke
Current Medicinal Chemistry Probiotics as an Adjuvant Therapy in Major Depressive Disorder
Current Neuropharmacology HSV-1-Derived Recombinant and Amplicon Vectors for Gene Transfer and Gene Therapy
Current Gene Therapy Evaluation of the Effect of α-L-Guluronic Acid (G2013) on COX-1, COX-2 Activity and Gene Expression for Introducing this Drug as a Novel NSAID with Immunomodulatory Property
Recent Patents on Inflammation & Allergy Drug Discovery Editorial [Hot Topic: Latest Developments in the Treatment of Inflammatory Disease (Guest Editor: David Fairlie)]
Current Medicinal Chemistry Recombinant Human Polyclonal Antibodies: A New Class of Therapeutic Antibodies Against Viral Infections
Current Pharmaceutical Design Using an Ancient Tool for Igniting and Propagating Immune Tolerance: IDO as an Inducer and Amplifier of Regulatory T Cell Functions
Current Medicinal Chemistry Nanocarriers for Effective Brain Drug Delivery
Current Topics in Medicinal Chemistry Functional and Molecular Ultrasound Imaging: Concepts and Contrast Agents
Current Medicinal Chemistry The Yin and Yang of Non-Neuronal α7-Nicotinic Receptors in Inflammation and Autoimmunity
Current Drug Targets The Contribution of γδ T Cells to the Pathogenesis of EAE and MS
Current Molecular Medicine Treatment of Viral Encephalitis
Central Nervous System Agents in Medicinal Chemistry Experimental Autoimmune Encephalomyelitis (EAE) Model of Cynomolgus Macaques Induced by Recombinant Human MOG1-125 (rhMOG1-125) Protein and MOG34-56 Peptide
Protein & Peptide Letters